Acino: change in management

Acino: change in management

Basle, December 18, 2009, 07.00 hrs - Dr. Wolfgang Niedermaier, Head Acino German Operations, has decided to leave the Acino Group for personal reasons by the end of 2009. In his function, he was directly responsible for and coordinated all activities of the Acino Group at the German location. The Board of Directors and Group Manage-ment thank Wolfgang Niedermaier for his dedicated and successful efforts and wish him much success in his future endeavors.


Effective January 1, 2010, Dr. Axel Müller, CEO of the Acino Group, will assume overall responsibility for Acino's German operations in addition to his current function.

Acino - a focused pharmaceutical company

Acino specializes in the development, registration and manufacture of generic and innovative pharmaceuticals using advanced drug delivery technologies, for which it also holds patents. With a focus on solid oral dosage forms with modified release of the active ingredient, transdermal the-rapeutic patches and biodegradable, subcutaneous implants, Acino supplies leading pharmaceu-tical companies throughout Europe. Acino offers the pharmaceutical industry a comprehensive range of services from product development and registration to sourcing, contract manufacturing, packaging and logistics. The Acino Group is headquartered in Basle (Switzerland), currently em-ploys approximately 400 staff and generated annual revenue of CHF 232 million in 2008. Acino Holding Ltd., the Group's parent, is listed on the SIX Swiss Exchange (SIX: ACIN).
 

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.